<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We investigated the efficacy of <z:chebi fb="0" ids="30621">arsenic trioxide</z:chebi> (ATO) in patients with refractory severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (SAA) </plain></SENT>
<SENT sid="1" pm="."><plain>A total of 5 consecutive adults were enrolled </plain></SENT>
<SENT sid="2" pm="."><plain>The patients received ATO at a dose of 0.15 mg/kg intravenously daily for 5 days every week for 8 weeks </plain></SENT>
<SENT sid="3" pm="."><plain>If necessary, a second course was performed after an interval of one week </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients achieved clinically significant responses to ATO </plain></SENT>
<SENT sid="5" pm="."><plain>The overall complete response rate and overall response rate at 17 weeks were 60% (3/5) and 100%(5/5), respectively </plain></SENT>
<SENT sid="6" pm="."><plain>So treatment with ATO may be a feasible approach in patients with refractory SAA </plain></SENT>
</text></document>